AnaptysBio, Inc.

声明：因水平有限，错误不可避免，或有些信息非最及时，欢迎留言指出。本文仅作医疗健康相关药物介绍，非治疗方案推荐（若涉及）;本文不构成任何投资建议。 10月30日，礼来发布2024年第三季度财报，前三季度营业收入315亿美元，同比增长27%，净利润61.8亿美元。Q3营收114.4亿美元，同比增长20.5%。 其中热门减肥药Mounjaro和Zepbound三季度收入不及市场预期，该公司将此归咎于批发渠道库存减少，因此下调了全年业绩预期（预计全年 454 亿美元至 460 亿美元）。前三季度，Moujaro销售额80.10亿美元，去年同期29.58亿美元，Zepbound销售额30.18亿美元。替尔泊肽合计销售额110亿美元，预计全年超过160亿美元。 目前礼来已投资数十亿美元扩大其Mounjaro和Zepbound的生产，其中包括在其印第安纳州工厂和爱尔兰设施上投资约70亿美元。 财报公布后，礼来美股盘前大跌逾10%。 此外，在研发管线方面，礼来宣布决定终止一款治疗难治性类风湿关节炎的PD-1激动剂抗体Peresolimab研究，Peresolimab为全球范围内临床进展最快的PD-1激动剂抗体。 Peresolimab最初由Anaptysbio研发，Anaptysbio今日股价盘前大跌30%。PD-1抑制剂抗体引领了整个肿瘤免疫领域的突破进展，但PD-1激动剂抗体则在自免适应症的探索中遇到了重大挫折。 关于peresolimab peresolimab是一种人源化 IgG1 单克隆抗体，可结合并激活 PD-1，有可能在不影响免疫库中剩余细胞的情况下恢复免疫稳态。2a期临床试验数据显示，中重度RA的成年患者（对常规抗风湿性疾病药物或生物靶向药物反应不足、反应丧失或副作用不可接受），每4周静脉注射一次700mg的peresolimab，治疗12周的DAS28-CRP（类风湿评分标准）较基线变化显著优于安慰剂。 参考资料： 礼来财报 -END- 2025CMC-CHINA药博会 • 展位火热预定中！

Biotech investment firm Samsara BioCapital has added three new venture partners in recent months to expand its network, support first-time CEOs in its portfolio and guide more companies by way of board seats. One of the venture partners also has government policy experience, giving the California firm an in-house expert to advise on some of the biggest legislative forces in drug development today, including the Inflation Reduction Act and the ongoing Biosecure bill. The eight-year-old firm has added former Chinook Therapeutics CEO Eric Dobmeier, ex-Atreca CEO John Orwin and previous Alnylam public policy and government relations leader Alan Eisenberg. Samsara now has 14 venture partners, founder and managing partner Srini Akkaraju told Endpoints News in an interview. The team’s expansion comes as Samsara’s portfolio companies have hit some key milestones in recent months, including multiple megarounds, EyeBio’s up to $3 billion exit to Merck , OnKure’s reverse merger with Reneo Pharmaceuticals, IPO planning at Upstream Bio and a Nasdaq listing for Alumis . Akkaraju is quite familiar with Dobmeier and Orwin by way of Seagen. Akkaraju served on the antibody-drug conjugate pioneer’s board for 17 years until 2020, during which Orwin was also a board member. Dobmeier had risen to the role of chief operating officer at the Seattle biotech before departing to become an executive at Silverback Therapeutics and then Chinook, which he oversaw until its $3.2 billion exit to Novartis last year. The Samsara founder said biotech is innovating at a faster clip than ever before, and the deal flow far exceeds the levels he saw in the early days of his investing career two decades ago. That calls for experienced veterans to help guide nascent companies. “The reality is the science and the innovation and the ideas, there’s more of them than experienced CEOs to run these [biotechs],” Akkaraju said. “But everybody has to be a first-time something, and first-time CEOs are always going to be there, and they’re an important part of our ecosystem. I personally think people like Eric and John are phenomenal to help these first-time CEOs do their job as well as they possibly can and grow a little bit faster into it.” Orwin was already chair of Samsara portfolio company Cargo Therapeutics. He’s also on the boards of Travere Therapeutics, AnaptysBio and Nested Therapeutics. Meanwhile, Eisenberg had spent about a decade at the Biotechnology Innovation Organization before working on government relations for Celgene and then Alnylam. “We’ve all been talking about Biosecure, we’ve been talking about the IRA for the last couple of years and the impact that will have and changes to Medicare Part D, etc. We read about it, we see it, and we talk to people about it. We get a little bit of, I’d say, a rudimentary understanding,” Akkaraju said. “Then, Alan’s come in and provided us a much greater level of understanding of this.” Investors could rely on outside experts and call them up when they need counsel on matters related to government policy, IRA implications and the like. But Akkaraju said he’d “rather have that person at the table all the time.” Akkaraju noted the trio of new team members — who are part-time — is not a sign that Samsara will ramp up the number of investments it makes. “It certainly has an impact on deal flow because all of these guys have great networks out there that will bring in opportunities,” Akkaraju said, but “it’s all about doing as good of a job as we possibly can in making a decision to do a deal and managing the investment and working with the portfolio company.”

SAN DIEGO, Aug. 29, 2024 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that Daniel Faga, president and chief executive officer of Anaptys, and/or other members of its senior management team, are scheduled to participate in multiple upcoming investor conferences: 2024 Wells Fargo Healthcare Conference, Boston, MA Format – Fireside chat and one-on-one investor meetingsDate and Time – Thursday, Sept. 5, 2024 at 10:15am ET / 7:15am PT Stifel 2024 Virtual Immunology and Inflammation Summit Format – Fireside chatDate and Time – Tuesday, Sept. 17, 2024 at 1:30pm ET / 10:30am PT 2024 Cantor Fitzgerald Global Healthcare Conference, New York, NY Format – Fireside chat and one-on-one investor meetingsDate and Time – Wednesday, Sept. 18, 2024 at 9:45am ET / 6:45am PT Live webcasts of the fireside chats will be available on the investor section of the Anaptys website at http://ir.anaptysbio.com/events. Replays of the webcasts will be available for at least 30 days following the events. About Anaptys Anaptys is a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics. It is developing immune cell modulators for autoimmune and inflammatory diseases, including two checkpoint agonists: ANB032, its BTLA agonist, in a Phase 2b trial for the treatment of atopic dermatitis and rosnilimab, its PD-1 agonist, in a Phase 2b trial for the treatment of rheumatoid arthritis and in a Phase 2 trial for the treatment of ulcerative colitis. It also has other immune cell modulator candidates in its portfolio, including ANB033, an anti-CD122 antagonist antibody, entering a Phase 1 trial and ANB101, a BDCA2 modulator antibody, in preclinical development. In addition, Anaptys has developed two cytokine antagonists available for out-licensing: imsidolimab, an anti-IL-36R antagonist, that has completed Phase 3 trials for the treatment of generalized pustular psoriasis, and etokimab, an anti-IL-33 antagonist that is Phase 2/3 ready. Anaptys has also discovered multiple therapeutic antibodies licensed to GSK in a financial collaboration for immuno-oncology, including an anti-PD-1 antagonist antibody (Jemperli (dostarlimab-gxly)) and an anti-TIM-3 antagonist antibody (cobolimab, GSK4069889). To learn more, visit www.AnaptysBio.com or follow us on LinkedIn and X. Contact:Nick MontemaranoSenior Director, Investor Relations and Strategic Communications 858.732.0178investors@anaptysbio.com